TRAW
Income statement / Annual
Last year (2025), Traws Pharma Inc.'s total revenue was $2.79 M,
an increase of 1,134.51% from the previous year.
In 2025, Traws Pharma Inc.'s net income was $9.17 M.
See Traws Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$2.79 M |
$226.00 K |
$226.00 K |
$226.00 K |
$226.00 K |
$231.00 K |
$2.18 M |
$1.23 M |
$787.00 K |
$5.55 M |
| Cost of Revenue |
$0.00
|
$12.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$2.79 M
|
$214.00 K
|
$226.00 K
|
$226.00 K
|
$226.00 K
|
$231.00 K
|
$2.18 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
0.95
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$12.14 M
|
$130.31 M
|
$11.43 M
|
$11.41 M
|
$7.30 M
|
$16.90 M
|
$15.54 M
|
$16.87 M
|
$19.03 M
|
$20.07 M
|
| General & Administrative Expenses |
$8.52 M
|
$12.29 M
|
$9.09 M
|
$8.45 M
|
$9.43 M
|
$8.33 M
|
$8.35 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.52 M
|
$12.29 M
|
$9.09 M
|
$8.45 M
|
$9.43 M
|
$8.33 M
|
$8.35 M
|
$7.59 M
|
$7.41 M
|
$9.08 M
|
| Other Expenses |
$0.00
|
-$93.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$20.67 M
|
$49.56 M
|
$20.52 M
|
$19.85 M
|
$16.72 M
|
$25.22 M
|
$23.88 M
|
$24.46 M
|
$26.44 M
|
$29.15 M
|
| Cost And Expenses |
$20.67 M
|
$49.57 M
|
$20.52 M
|
$19.85 M
|
$16.72 M
|
$25.22 M
|
$23.88 M
|
$24.51 M
|
$26.52 M
|
$29.25 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$61.00 K
|
$12.00 K
|
$16.00 K
|
$14.00 K
|
$14.00 K
|
$13.00 K
|
$14.00 K
|
$55.00 K
|
$88.00 K
|
$96.00 K
|
| EBITDA |
-$17.81 M |
-$166.51 M |
-$20.28 M |
-$19.61 M |
-$16.48 M |
-$24.98 M |
-$21.69 M |
-$20.48 M |
-$23.99 M |
-$19.56 M |
| EBITDA Ratio |
-6.38
|
-736.77
|
-89.74
|
-86.78
|
-72.93
|
-108.14
|
-9.93
|
-16.68
|
-30.48
|
-3.53
|
| Operating Income Ratio |
-6.41
|
-218.35
|
-89.81
|
-86.85
|
-72.99
|
-108.19
|
-9.94
|
-18.96
|
-32.7
|
-4.27
|
| Total Other Income/Expenses Net |
$27.05 M
|
-$117.18 M
|
$1.35 M
|
$663.00 K
|
$333.00 K
|
-$160.00 K
|
$206.00 K
|
$2.75 M
|
$1.66 M
|
$4.05 M
|
| Income Before Tax |
$9.17 M
|
-$166.52 M
|
-$18.95 M
|
-$18.96 M
|
-$16.16 M
|
-$25.15 M
|
-$21.49 M
|
-$20.53 M
|
-$24.08 M
|
-$19.65 M
|
| Income Before Tax Ratio |
3.29
|
-736.83
|
-83.84
|
-83.91
|
-71.52
|
-108.89
|
-9.85
|
-16.72
|
-30.6
|
-3.54
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4.00 K
|
$10.00 K
|
-$124.00 K
|
$13.00 K
|
$14.00 K
|
| Net Income |
$9.17 M
|
-$54.67 M
|
-$18.95 M
|
-$18.96 M
|
-$16.16 M
|
-$25.16 M
|
-$21.50 M
|
-$20.57 M
|
-$24.09 M
|
-$19.67 M
|
| Net Income Ratio |
3.29
|
-241.92
|
-83.84
|
-83.91
|
-71.52
|
-108.9
|
-9.85
|
-16.75
|
-30.61
|
-3.55
|
| EPS |
0.83 |
-35.21 |
-22.569 |
-22.6752 |
-24.006 |
-54.2062 |
-560.58 |
-1870.6912 |
-15056 |
-24975 |
| EPS Diluted |
0.82 |
-35.21 |
-22.569 |
-22.6752 |
-24.006 |
-54.2062 |
-560.58 |
-1870.6912 |
-15056 |
-24975 |
| Weighted Average Shares Out |
$8.23 M
|
$1.55 M
|
$839.55 K
|
$836.33 K
|
$673.29 K
|
$464.10 K
|
$38.36 K
|
$11.00 K
|
$1.60 K
|
$786.96
|
| Weighted Average Shares Out Diluted |
$8.38 M
|
$1.55 M
|
$839.55 K
|
$836.33 K
|
$673.29 K
|
$464.10 K
|
$38.36 K
|
$11.00 K
|
$1.60 K
|
$786.96
|
| Link |
|
|
|
|
|
|
|
|
|
|
